[go: up one dir, main page]

WO2012060790A2 - Formulations de cefpodoxime proxétil dispersibles dans l'eau - Google Patents

Formulations de cefpodoxime proxétil dispersibles dans l'eau Download PDF

Info

Publication number
WO2012060790A2
WO2012060790A2 PCT/TR2011/000255 TR2011000255W WO2012060790A2 WO 2012060790 A2 WO2012060790 A2 WO 2012060790A2 TR 2011000255 W TR2011000255 W TR 2011000255W WO 2012060790 A2 WO2012060790 A2 WO 2012060790A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
agent
composition according
range
carboxymethyl cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000255
Other languages
English (en)
Other versions
WO2012060790A3 (fr
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012060790A2 publication Critical patent/WO2012060790A2/fr
Publication of WO2012060790A3 publication Critical patent/WO2012060790A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to pharmaceutical formulations comprising cefpodoxime and optionally clavulanic acid or derivatives thereof.
  • Cefpodoxime proxetil is a third generation cephalosporin. Due to this feature, it is indicated for the treatment of infections caused by gram positive and gram negative bacteria.
  • Clavulanic acid and derivatives thereof are known as the beta-lactamase inhibitors which withstand the beta-lactamase-originated resistance mechanism by suppressing the activity of beta-lactamase enzymes produced by bacteria.
  • Clavulanic acid and derivatives thereof can optionally be formulated as combined with antibiotics in order to increase efficiency of beta-lactam derivative antibiotics.
  • Tablets which contain 100 mg and 200 mg of cefpodoxime are available on the market. When these tablets containing 100 or 200 mg of active agent are formulated with excipients, they become quite large in size and this makes use of this dosage form inconvenient for patients who have swallowing difficulties, especially for pediatric and geriatric patients.
  • cefpodoxime proxetil has quite low water solubility; therefore bioavailability of tablet forms thereof is rather low. It is known that efficiency of a drug depends on the design of the pharmaceutical formulation to a great extent. When highly hydrophobic nature of cephalosporins, especially DCpodoxime, are taken into consideration, it is seen that selecting each agent to be used in the formulation carefully is significant to attain to the desired level of bioavailability in the dosage forms constituted.
  • the subject matter of the present invention is formulations comprising water dispersible cefpodoxime which comprise a viscosity agent consisting of hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination and optionally clavulanic acid or derivatives thereof. It has surprisingly been seen that powder, tablet and/or granules comprising the active agent cefpodoxime, which has rather low solubility, and formulated with the viscosity agent comprising the combination of hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent constitute a suspension which is dispersed in water without gelling.
  • pharmaceutical dosage forms in the form of water dispersible powder, tablet and/or granule a) can be taken by patients more comfortably than the solid dosage forms as they disperse in water homogeneously and their bioavailability is superior to said solid dosage forms; b) thus, the problem of gelling which is frequently encountered in cefpodoxime formulations is overcome in this way.
  • Cefpodoxime that can be used in water dispersible powder, tablet and/or granule formulations of the present invention can be in the form of its esters, solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free form and/or a combination thereof.
  • cefpodoxime proxetil is used in the present invention.
  • water dispersible powder , tablet and/or granule comprises single dose effervescent powder, tablets and/or granules; single dose water dispersible powder, tablets and granules; multiple dose powder, tablets and granules which are dispersed in water to form suspension; single dose water soluble powder, tablets and granules; multiple dose water soluble powder, tablets and granules, preferably in the form of multiple dose powder dispersed in water to form suspension or single dose water dispersible powder, tablets or granules.
  • one aspect of the present invention is water dispersible powder, tablet and/or granule formulations comprising cefpodoxime as the active agent and viscosity agent composition comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination.
  • Another aspect of the present invention is water dispersible powder, tablet and/or granule formulations comprising cefpodoxime as the active agent; viscosity agent composition comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination; and additionally other pharmaceutically acceptable excipients.
  • the water dispersible powder, tablet and/or granule formulation can comprise various excipients such as, but not limited to, binders, glidants, lubricants, humectants, disintegrants, diluents, basic agents, acidic agents, taste regulating agents, flavoring agents, preservative agents and optionally effervescent couple.
  • excipients such as, but not limited to, binders, glidants, lubricants, humectants, disintegrants, diluents, basic agents, acidic agents, taste regulating agents, flavoring agents, preservative agents and optionally effervescent couple.
  • the binder that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, methyl cellulose, povidone or the combination thereof.
  • the lubricant that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or the combination thereof.
  • talc is used as lubricant in the formulation of the present invention.
  • the glidant that can be used in the water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising magnesium silicate, silicon dioxide, starch, talc, tribasic calcium phosphate or the combination thereof.
  • silicon dioxide is used as glidant in the formulation of the present invention.
  • the humectant that can be used in the water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising anhydrous sodium sulphate, silica gel and potassium carbonate or the combination thereof.
  • the disintegrant that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate and starch or combinations thereof.
  • the diluent that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch, xylitol or combinations thereof.
  • the basic agent that can be used in the water dispersible powder, tablet and/or granule formulation of the present invention can be selected from a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium bicarbonate or combinations thereof.
  • the acidic agent that can be used in the water dispersible powder, tablet and/or granule formulation of the present invention can be selected from a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or combinations thereof.
  • citric acid is used in the formulation of the present invention as acidic agent.
  • the taste regulating agent that can be used in water dispersible powder, tablet and/or granule formulation of the present invention can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharine, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof.
  • the preservative agent that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising methylparaben, ethylparaben, butylparaben, sorbic acid, tertiary ammonium salts, potassium sorbate, benzoic acid and/or salts thereof (sodium benzoate) and benzyl alcohol or combinations thereof.
  • the effervescent couple that can optionally be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid etc. and basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate and potassium hydrogen carbonate etc.
  • the viscosity agent that can be used in water dispersible powder, tablet and/or granule formulation of the present invention is composed of hydroxypropyl cellulose and at least one carboxymethylcellulose derivative agent.
  • the ratio of the carboxymethyl cellulose derivative agents to hydroxypropyl cellulose used in viscosity agent combination of the present invention is in the range of 15:1 and 5:1 by weight, preferably in the range of 12:1 and 6:1 by weight, more preferably in the range of 10:1 and 7:1 by weight.
  • carboxymethyl derivative agent refers to alkali and alkaline- earth salts of carboxymethyl cellulose.
  • Carboxymethyl cellulose derivative agent can be selected from a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium or combinations thereof.
  • the inventors have found that water dispersity of a pharmaceutical composition obtained by use of combination of carboxymethyl cellulose sodium and carboxymethyl cellulose calcium is better than the other pharmaceutical compositions in which only one of said agents is used.
  • present invention relates to water dispersible cefpodoxime formulations comprising a viscosity agent combination comprising hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium.
  • the ratio of carboxymethyl cellulose calcium to carboxymethyl cellulose sodium in said viscosity agent combination is in the range of 5: 1 and 1 :1 by weight, preferably in the range of 4:1 and 2:1 by weight.
  • the water dispersible powder, tablet and granule formulation of the present invention can comprise cefpodoxime in the range of 20-800 mg or its pharmaceutically acceptable esters, salts, hydrates, solvates or a combination thereof in an equal amount.
  • the water dispersible powder, tablet and granule formulation of the present invention can comprise 5-60% of cefpodoxime or its pharmaceutically acceptable esters, solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms in proportion to total weight of unit dose.
  • the water dispersible powder, tablet and granule formulation of the present invention can comprise 5-60 % of cefpodoxime and at least one; binder in the range of 0-40%; glidant in the range of 0.5-5%; lubricant in the range of 1-10%; humectant in the range of 0-40%; disintegrant and/or disintegrants in the range of 0-20%; diluent in the range of 35-65%; basic agent in the range of 0-40%; acidic agent in the range of 0.1-40%; taste regulating agent in the range of 5-30%; viscosity agent in the range of 2-15%; flavoring agent in the range of 0.1-5%; preservative agent in the range of 0-5% and optionally effervescent couple in the range of 0- 85% in proportion to the total weight of unit dose amount.
  • the formulation of the present invention can be used for pharmaceutical ⁇ compositions comprising clavulanic acid or derivatives thereof along with cefpodoxime.
  • the present invention relates to pharmaceutical compositions comprising cefpodoxime and clavulanic acid or derivatives thereof, viscosity agent composition comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination; and optionally pharmaceutically acceptable excipients in addition.
  • Clavulanic acid that can optionally be used in the pharmaceutical composition of the present invention can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or in free form and/or a combination thereof.
  • potassium clavulanate is used in the present invention.
  • the pharmaceutical composition of the present invention can comprise clavulanic acid in the range of 50-500 mg or its pharmaceutically acceptable salts, hydrates, solvates or the combination thereof in an equal amount.
  • Clavulanic acid and its derivatives are extremely susceptible to moisture.
  • potassium clavulanate is preferably used with a humectant in the ratio of 1 :1 in the pharmaceutical composition of the present invention.
  • colloidal silica for instance colloidal silica anhydrous, magnesium trisilicate, cellulose powder, magnesium oxide, calcium silicate, starch, microcrystalline cellulose, talc can be used as the humectant.
  • potassium clavulanate is preferably used with syloid in the ratio of 1 : 1.
  • the pharmaceutical composition of the present invention can comprise 5-50% of clavulanic acid in proportion to total weight of unit dose amount or pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
  • the present invention relates to processes that can be used for preparation of water dispersible powder, tablet and/or granule formulations comprising pharmaceutically acceptable excipients in addition to cefpodoxime as the active agent.
  • the process of the present invention comprises granulation of the active agent cefpodoxime proxetil by conventional wet and/or dry granulation methods; or powdering cefpodoxime proxetil and other excipients after mixing them by dry blending method and optionally compressing tablets.
  • the powder, tablet and/or granules obtained are dispersed in water before use by patients and taken in liquid form.
  • Another aspect of the present invention is that the formulation prepared according to said invention is used in the treatment of diseases related with infections caused by gram negative and gram positive bacteria.
  • Water dispersible tablets of the present invention can be prepared as specified below, yet the invention is not restricted to these examples.
  • EXAMPLE 1 Formulation and process for preparation of water dispersible granule
  • a method for preparation of water dispersible granule given in the example comprises, but not limited to, dissolving cefpodoxime proxetil in a suitable solvent; and granulating the diluent with this solution; and drying and then mixing the obtained granules with the other excipients.
  • a method for preparation of water dispersible granule given in this example comprises, but not limited to, dissolving cefpodoxime proxetil in a suitable solvent; and granulating the diluent with this solution; and drying and then mixing the granules obtained with potassium clavylanate-syloid (1 :1) and the other excipients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formulations pharmaceutiques comprenant du cefpodoxime proxétil.
PCT/TR2011/000255 2010-11-05 2011-11-03 Formulations de cefpodoxime proxétil dispersibles dans l'eau Ceased WO2012060790A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/09168 2010-11-05
TR2010/09168A TR201009168A2 (tr) 2010-11-05 2010-11-05 Suda dağılan sefpodoksim proksetil formülasyonları.

Publications (2)

Publication Number Publication Date
WO2012060790A2 true WO2012060790A2 (fr) 2012-05-10
WO2012060790A3 WO2012060790A3 (fr) 2012-09-20

Family

ID=45446166

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2011/000251 Ceased WO2012060786A2 (fr) 2010-11-05 2011-11-03 Formulations de proxétil cefpodoxime comprenant un agent de viscosité
PCT/TR2011/000255 Ceased WO2012060790A2 (fr) 2010-11-05 2011-11-03 Formulations de cefpodoxime proxétil dispersibles dans l'eau

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000251 Ceased WO2012060786A2 (fr) 2010-11-05 2011-11-03 Formulations de proxétil cefpodoxime comprenant un agent de viscosité

Country Status (2)

Country Link
TR (1) TR201009168A2 (fr)
WO (2) WO2012060786A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2833872A1 (fr) * 2012-04-04 2015-02-11 Mahmut Bilgic Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique
CN103142506B (zh) * 2013-04-03 2015-02-25 天津医药集团津康制药有限公司 一种头孢泊肟酯颗粒剂及其制备方法
CN103230367B (zh) * 2013-05-07 2014-11-12 山东罗欣药业集团股份有限公司 一种头孢泊肟酯组合物干混悬剂及其制备方法
MX2017007287A (es) * 2014-12-01 2017-08-25 Sun Pharmaceutical Ind Ltd Composicion de cefpodoxima proxetil de liberacion prolongada.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049118A2 (fr) 1980-09-30 1982-04-07 Sankyo Company Limited Dérivés de céphalosporines, leur préparation et compositions les contenant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303149T1 (de) * 2001-02-27 2005-09-15 Ranbaxy Lab Ltd Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
EA200500213A1 (ru) * 2002-07-16 2005-08-25 Рэнбакси Лабораториз Лимитед Диспергируемые таблетки для орального назначения
WO2007017895A2 (fr) * 2005-05-05 2007-02-15 Lupin Limited Compositions pharmaceutiques stabilisees de cephalosporines
TR201002878A2 (tr) * 2010-04-13 2011-10-21 Bi̇lgi̇ç Mahmut Sefpodoksim proksetil içeren farmasötik bileşimler.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049118A2 (fr) 1980-09-30 1982-04-07 Sankyo Company Limited Dérivés de céphalosporines, leur préparation et compositions les contenant

Also Published As

Publication number Publication date
WO2012060786A3 (fr) 2012-07-26
WO2012060786A2 (fr) 2012-05-10
TR201009168A2 (tr) 2012-05-21
WO2012060790A3 (fr) 2012-09-20

Similar Documents

Publication Publication Date Title
EP2528589B1 (fr) Formulations effervescentes stables contenant du céfaclor
WO2011142731A2 (fr) Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération
WO2012060788A1 (fr) Formulations de céphalosporines avec teneur en humidité contrôlée
WO2012060790A2 (fr) Formulations de cefpodoxime proxétil dispersibles dans l'eau
EP2608776A2 (fr) Préparations de cefpodoxime proxétil
EP2515860B1 (fr) Compositions pharmaceutiques améliorées comprenant cefdinir
EP2568957A1 (fr) Composition pharmaceutique comprenant la céfixime et un composé dérivé de l'acide clavulanique
WO2011129792A1 (fr) Formulations dispersibles dans l'eau comprenant le cefpodoxime proxétil
US20130129791A1 (en) Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
WO2011093828A2 (fr) Formes posologiques solides comprenant du cefprozil
EP2566451B1 (fr) Composition pharmaceutique contentant de cefditoren pivoxil
EP2515858A1 (fr) Composition pharmaceutique très pure
WO2012060787A1 (fr) Comprimés contenant du cefdinir
WO2012060791A2 (fr) Procédé de production de compositions pharmaceutiques comprenant du cefdinir
EP2515859A1 (fr) Formulation effervescente à dispersion rapide
WO2012026908A2 (fr) Préparations de cefpodoxime proxétil comprenant un agent régulateur de goût
WO2011152805A2 (fr) Composition pharmaceutique comprenant de l'acide clavulanique et du cefpodoxime proxétil
WO2011139255A2 (fr) Compositions pharmaceutiques comprenant du céfétamet
WO2012060792A1 (fr) Compositions pharmaceutiques comprenant au minimum 6% en poids de délitants
EP2575777A1 (fr) Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique
WO2012060793A2 (fr) Procédé de préparation de formulations de cefdinir
WO2012078121A2 (fr) Forme posologique orale solide comprenant cefdinir
WO2013151517A1 (fr) Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11805269

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11805269

Country of ref document: EP

Kind code of ref document: A2